COVID-19 疫苗接种在孕妇怀孕期间的覆盖情况- 2020 年 12 月 14 日至 2021 年 5 月 8 日,美国 8 个综合医疗保健组织。

COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021.

出版信息

MMWR Morb Mortal Wkly Rep. 2021 Jun 18;70(24):895-899. doi: 10.15585/mmwr.mm7024e2.

Abstract

COVID-19 vaccines are critical for ending the COVID-19 pandemic; however, current data about vaccination coverage and safety in pregnant women are limited. Pregnant women are at increased risk for severe illness and death from COVID-19 compared with nonpregnant women of reproductive age, and are at risk for adverse pregnancy outcomes, such as preterm birth (1-4). Pregnant women are eligible for and can receive any of the three COVID-19 vaccines available in the United States via Emergency Use Authorization.* Data from Vaccine Safety Datalink (VSD), a collaboration between CDC and multiple integrated health systems, were analyzed to assess receipt of ≥1 dose (first or second dose of the Pfizer-BioNTech or Moderna vaccines or a single dose of the Janssen [Johnson & Johnson] vaccine) of any COVID-19 vaccine during pregnancy, receipt of first dose of a 2-dose COVID-19 vaccine (initiation), or completion of a 1- or 2-dose COVID-19 vaccination series. During December 14, 2020-May 8, 2021, a total of 135,968 pregnant women were identified, 22,197 (16.3%) of whom had received ≥1 dose of a vaccine during pregnancy. Among these 135,968 women, 7,154 (5.3%) had initiated and 15,043 (11.1%) had completed vaccination during pregnancy. Receipt of ≥1 dose of COVID-19 vaccine during pregnancy was highest among women aged 35-49 years (22.7%) and lowest among those aged 18-24 years (5.5%), and higher among non-Hispanic Asian (Asian) (24.7%) and non-Hispanic White (White) women (19.7%) than among Hispanic (11.9%) and non-Hispanic Black (Black) women (6.0%). Vaccination coverage increased among all racial and ethnic groups over the analytic period, likely because of increased eligibility for vaccination and increased availability of vaccine over time. These findings indicate the need for improved outreach to and engagement with pregnant women, especially those from racial and ethnic minority groups who might be at higher risk for severe health outcomes because of COVID-19 (4). In addition, providing accurate and timely information about COVID-19 vaccination to health care providers, pregnant women, and women of reproductive age can improve vaccine confidence and coverage by ensuring optimal shared clinical decision-making.

摘要

COVID-19 疫苗对于结束 COVID-19 大流行至关重要;然而,目前关于孕妇疫苗接种覆盖率和安全性的数据有限。与育龄非孕妇相比,孕妇患 COVID-19 重症和死亡的风险增加,并且存在不良妊娠结局的风险,例如早产(1-4)。孕妇有资格通过紧急使用授权(EUA)获得并可接种美国现有的三种 COVID-19 疫苗中的任何一种*。利用疾病预防控制中心(CDC)与多个综合医疗系统合作的疫苗安全数据链接(VSD)的数据,评估了≥1 剂(辉瑞-BioNTech 或 Moderna 疫苗的首剂或第二剂或 Janssen[强生]疫苗的单剂)任何 COVID-19 疫苗在怀孕期间的接种情况、2 剂 COVID-19 疫苗的首剂接种(起始)或 1 或 2 剂 COVID-19 疫苗接种系列的完成情况。在 2020 年 12 月 14 日至 2021 年 5 月 8 日期间,共确定了 135968 名孕妇,其中 22197 名(16.3%)在怀孕期间接种了≥1 剂疫苗。在这 135968 名妇女中,有 7154 名(5.3%)开始接种,有 15043 名(11.1%)完成了怀孕期间的接种。在怀孕期间接种≥1 剂 COVID-19 疫苗的比例在 35-49 岁的女性中最高(22.7%),在 18-24 岁的女性中最低(5.5%),而非西班牙裔亚裔(亚裔)(24.7%)和非西班牙裔白人(白人)女性(19.7%)高于西班牙裔(11.9%)和非西班牙裔黑人(黑人)女性(6.0%)。在分析期间,所有种族和族裔群体的疫苗接种率都有所增加,这可能是由于随着时间的推移,疫苗接种的资格扩大和疫苗供应增加。这些发现表明需要加强对孕妇的宣传和接触,特别是对那些可能因 COVID-19 而面临更严重健康后果风险的种族和族裔少数群体(4)。此外,向医疗保健提供者、孕妇和育龄妇女提供有关 COVID-19 疫苗接种的准确和及时信息,可以通过确保最佳的共同临床决策来提高疫苗信心和覆盖率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3276/8220952/1fc99630cfe9/mm7024e2-F.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索